Wentworth expands Area53 life sciences platform with $200 million investment in North Ryde

Wentworth and BlackRock Real Estate have announced a significant $200 million acquisition in North Ryde which will see the creation of a new life science precinct.

Via their Area 53 platform the two assets at 5–11 and 14 Julius Avenue, North Ryde will support the growing demand for specialised R&D and lab focused facilities to support Australia's growing life sciences sector.

This follows a previous investment by Area 53 into North Ryde R&D facility for Teva Pharmaceuticals Australian HQ.

Connect Macquarie Park Innovation District welcomes the continued investment into the Macquarie Park Innovation District by Area 53 and looks forward to working with new owners and tenants to create a connected ecosystem across the district.

Previous
Previous

Aegros secures funding for Macquarie Park Plasma Fractionation facility

Next
Next

MPark precinct nears completion with topping out cermony